AlaGln treatment decreased IL-8 levels by 2.2 pg/ml (CI 0.1 to 4.3, p<0.05) in the peritonitis-positive subgroup, in contrast to a non-significant increase of 1.1 pg/ml (CI -0.1 to 2.3) in patients without peritonitis (Fig 6). Here, CXCL8 is linked to peritonitis.